FIELD: organic synthesis.
SUBSTANCE: invention provides new method for preparing amorphous atorvastatine, i.e. hemi-calcium salt of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-{(phenylamino)carbonyl]-1H-pyrrol -1-heptanoic acid. Method comprises (i) preparation of atorvastatine solution in one or several first-type solvents selected from low-molecular alcohols, ketones, and esters, in which atorvastatine is soluble; (ii) preparation of mixture of the above solution with one or several second-type solvents selected from ethers, resulting in precipitation of atorvastatine; and (iii) separation of above precipitate from solvent mixture.
EFFECT: expanded atorvastatine synthesis possibilities.
16 cl, 2 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATION OF NONCRYSTALLINE CALCIUM ATORVASTATIN | 2002 |
|
RU2324679C2 |
| METHOD OF AMORPHOUS CALCIUM ATORVASTATIN OBTAINING | 2005 |
|
RU2330840C1 |
| METHOD FOR OBTAINING CRYSTALLINE FORM 8 SOPHOSBUVIR (VERSIONS) | 2019 |
|
RU2745293C1 |
| METHOD FOR OBTAINING AMORPHOUS CO-EVAPORATES OF CLADRIBIN WITH CYCLODEXTRINS | 2021 |
|
RU2758436C1 |
| 3-[2-(DIMETHYLAMINO)METHYL-(CYCLOHEX-1-YL)]PHENOL MALEATE AND ITS CRYSTALLINE FORMS | 2006 |
|
RU2434845C2 |
| AMORPHOUS 42-ESTER OF RAPAMYCIN AND 3-HYDROXY-2(HYDROXYMETHYL)-2-METHYLPROPANOIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAING IT | 2004 |
|
RU2345999C2 |
| CRYSTALLINE FORMS OF [R[(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROL-1-HEPTANOIC ACID | 2004 |
|
RU2315755C2 |
| ATORVASTATIN CALCIUM IN PHARMACEUTICAL FORMULATION, ITS COMPOSITION AND ATORVASTATIN CALCIUM-CONTAINING PHARMACEUTICAL PRESCRIPTION | 2002 |
|
RU2293555C2 |
| AMORPHOUS CALCIUM ATORVASTATINE PREPARATION METHOD | 2000 |
|
RU2255932C2 |
| POLYMORPHIC FORMS OF MACROCYCLIC HCV INHIBITOR | 2008 |
|
RU2533830C2 |
